Selina Luger named chair of ECOG-ACRIN Leukemia Committee

Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

Novartis presented positive results from the pivotal phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology meeting.

May 31, 2024

Vol.50 No.22

In Brief

Deming, Wakelee, Mouhieddine receive ECOG-ACRIN 2024 scientific leadership, mentorship awards

Dustin A. Deming, Heather A. Wakelee, and Tarek H. Mouhieddine were named recipients of the ECOG-ACRIN Cancer Research Group annual scientific awards, which are funded by the ECOG Research & Education Foundation.

May 17, 2024

Vol.50 No.20

In Brief

Matt Kalaycio named chair of board of directors at NCCN

Matt Kalaycio was named chair of the board of directors at the National Comprehensive Cancer Network. Christopher H. Lieu was elected as vice chair, succeeding Kalaycio in the position he has held since 2022.

April 12, 2024

Vol.50 No.15

In Brief

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Christopher Hourigan, a senior investigator and chief of the Laboratory of Myeloid Malignancies at the National Institutes of Health, will join Virginia Tech as a professor with the institute and director of its Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

April 05, 2024

Vol.50 No.14

Clinical Roundup

USC researchers find genetic variant contributing to disparities in childhood leukemia risk

Researchers from the University of Southern California found a genetic variant contributing to disparities in childhood leukemia risk. The variant, located on the IKZF1 gene, helps explain why Hispanic/Latino children face a higher risk of acute lymphoblastic leukemia and offers insights about what causes the disease.

March 29, 2024

Vol.50 No.13

Selina Luger named chair of ECOG-ACRIN Leukemia Committee

YOU MAY BE INTERESTED IN

Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

Deming, Wakelee, Mouhieddine receive ECOG-ACRIN 2024 scientific leadership, mentorship awards

Matt Kalaycio named chair of board of directors at NCCN

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

USC researchers find genetic variant contributing to disparities in childhood leukemia risk

Renew today!

Subscriber content

Login